Found 15 results
Filters: Author is Min, Irene M  [Clear All Filters]
2023
Limberg J, Egan CE, Gray KD, Singh M, Loewenstein Z, Yang Y, Riascos MCristina, Asadi HAl, Safe P, Eshaky SEl et al..  2023.  Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.. Mol Cancer Res. 21(5):397-410.
Yang Y, Louie R, Puc J, Vedvyas Y, Alcaina Y, Min IM, Britz M, Luciani F, Jin MM.  2023.  Chimeric Antigen Receptor T Cell Therapy Targeting Epithelial Cell Adhesion Molecule in Gastric Cancer: Mechanisms of Tumor Resistance.. Cancers (Basel). 15(23)
Yang Y, Yang H, Alcaina Y, Puc J, Birt A, Vedvyas Y, Gallagher M, Alla S, Riascos MCristina, McCloskey JE et al..  2023.  Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models.. Nat Commun. 14(1):2068.
2021
Yang Y, McCloskey JE, Yang H, Puc J, Alcaina Y, Vedvyas Y, Gallegos AAGomez, Ortiz-Sánchez E, de Stanchina E, Min IM et al..  2021.  Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.. Cancer Immunol Res. 9(10):1158-1174.
Egan CE, Stefanova D, Ahmed A, Raja VJ, Thiesmeyer JW, Chen KJ, Greenberg JA, Zhang T, He B, Finnerty BM et al..  2021.  CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.. Thyroid. 31(10):1481-1493.
2020
Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, Stefanova D, Gray KD, Min IM, Zarnegar R et al..  2020.  Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer.. Mol Ther Oncolytics. 18:587-601.
Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SEl, Yang Y, Shevlin E, Zaman M, Ullmann TM, Liang H et al..  2020.  PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.. Clin Cancer Res. 26(22):6003-6016.
Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu Y-MS, Hsu J-M, van Basien K, Gaudet I et al..  2020.  Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.. Sci Rep. 10(1):12733.
2019
Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu Y-MS, Hsu J-M, Van Besien K, Gaudet I et al..  2019.  Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy.. Sci Rep. 9(1):10634.
2017
Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, Moore MD, Wang W, Park S, Park S et al..  2017.  CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.. Clin Cancer Res. 23(24):7569-7583.
Park S, Shevlin E, Vedvyas Y, Zaman M, Park S, Hsu Y-MS, Min IM, Jin MM.  2017.  Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity.. Sci Rep. 7(1):14366.
2016
Vedvyas Y, Shevlin E, Zaman M, Min IM, Amor-Coarasa A, Park S, Park S, Kwon K-W, Smith T, Luo Y et al..  2016.  Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.. JCI Insight. 1(19):e90064.
2014
Meng H-W, Pagano JM, White BS, Toyoda Y, Min IM, Craighead HG, Shalloway D, Lis JT, Xiao K, Jin MM.  2014.  Discovering aptamers by cell-SELEX against human soluble growth factors ectopically expressed on yeast cell surface.. PLoS One. 9(3):e93052.
2013
Kim S, Min IM, Ren S, Spector A, Jin MM, Lis JT.  2013.  Development of temperature-sensitive mutants of the Drosophila melanogaster P-TEFb (Cyclin T/CDK9) heterodimer using yeast two-hybrid screening.. Biochem Biophys Res Commun. 433(2):243-8.
Bae H, Ren S, Kang J, Kim M, Jiang Y, Jin MM, Min IM, Kim S.  2013.  Sol-gel SELEX circumventing chemical conjugation of low molecular weight metabolites discovers aptamers selective to xanthine.. Nucleic Acid Ther. 23(6):443-9.